Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France

American Journal of Hematology

Volumn 90, Issue 4, 2015, Pages 301-305

  Moulis, Guillaume ^a,b,c   Lapeyre Mestre, Maryse ^a,b,c   Mahévas, Matthieu ^d   Montastruc, Jean Louis ^a,b,c   Sailler, Laurent ^a,b,c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; RITUXIMAB; BACTERIAL VACCINE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FRANCE; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; HUMORAL IMMUNE DEFICIENCY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SPLENECTOMY; STREPTOCOCCUS PNEUMONIAE; VACCINATION; BACTERIAL INFECTIONS; COHORT ANALYSIS; DRUG ADMINISTRATION; IMMUNOLOGY; MICROBIOLOGY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BACTERIAL INFECTIONS; BACTERIAL VACCINES; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC RESEARCH DESIGN; FEMALE; FRANCE; HUMANS; IMMUNOLOGIC FACTORS; LOGISTIC MODELS; MALE; PRACTICE GUIDELINES AS TOPIC; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SPLENECTOMY; VACCINATION;

EID: 84925361974     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23930     Document Type: Article

References (42)

1. Lo E, Deane S. Diagnosis and classification of immune-mediated thrombocytopenia. Autoimmun Rev 2014;13:577-583.
2. Deane S, Teuber SS, Gershwin ME. The geoepidemiology of immune thrombocytopenic purpura. Autoimmun Rev 2010;9:A342-A349.
3. Provan D, Stasi R, Newl AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-186.
4. Neunert C, Lim W, Crowther M, et al. The American society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-4207.
5. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009;113:2386-2393.
6. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American society of hematology. Blood 1996;88:3-40.
7. Moulis G, Palmaro A, Montastruc J-L, et al. Epidemiology of incident immune thrombocytopenia in France: A nationwide population-based study. Blood 2014;124:3308-3315.
8. Haute Autorité de Santé. Purpura thrombopénique immunologique de l'enfant et de l'adulte. Protocole national de diagnostic et de soins. 2009. Available at: http://www.has-sante.fr/portail/upload/docs/application/pdf/2009&-12/ald_2_pnds_pti_imune_enft_adulte_web.pdf. Accessed on July 1, 2014.
9. Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: The choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012;120:960-969.
10. Khellaf M, Charles-Nelson A, Fain O, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: Results from a prospective registry including 248 patients. Blood 2014;124:3228-3236
11. Moulis G, Lapeyre-Mestre M, Montastruc J-L, Sailler L. Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study. Autoimmun Rev 2015;14:168-173.
12. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104:2623-2634.
13. Kyaw MH, Holmes EM, Toolis F, et al. Evaluation of severe infection and survival after splenectomy. Am J Med 2006;119:276.e1-276.e7.
14. Thomsen RW, Schoonen WM, Farkas DK, et al. Risk for hospital contact with infection in patients with splenectomy: A population-based cohort study. Ann Intern Med 2009;151:546-555.
15. Wasserstrom H, Bussel J, Lim LC-L, Cunningham-Rundles C. Memory B cells and pneumococcal antibody after splenectomy. J Immunol 2008;181:3684-3689.
16. Waghorn DJ. Overwhelming infection in asplenic patients: Current best practice preventive measures are not being followed. J Clin Pathol 2001;54:214-218.
17. Vianelli N, Palandri F, Polverelli N, et al. Splenectomy as a curative treatment for immune thrombocytopenia: A retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica 2013;98:875-880. doi:10.3324/haematol.2012.075648.
18. Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012;119:5989-5995.
19. Nazi I, Kelton JG, Larché M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 2013;122:1946-1953.
20. McCrae KR. Better late than never? Blood 2013;122:1844-1845. doi:10.1182/blood-2013-07-515478.
21. Moulis G, Sailler L, Sommet A, et al. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: An adjusted comparison of mortality and morbidity. Am J Hematol 2014;89:41-46.
22. Levy R, Mahévas M, Galicier L, et al. Profound symptomatic hypogammaglobulinemia: A rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature. Autoimmun Rev 2014;13:1055-1063.
23. Moulis G, Lapeyre-Mestre M, Adoue D Sailler L. Epidemiology, pharmacoepidemiology of immune thrombocytopenia: Methodology of the FAITH study and of the CARMEN registry. Therapie 2014;69:437-448.
24. Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique 2010;58:286-290.
25. Tuppin P, Samson S, Weill A, Ricordeau P, Allem H. Seasonal influenza vaccination coverage in france during two influenza seasons (2007 and 2008) and during a context of pandemic influenza a(H1N1) in 2009. Vaccine 2011;29:4632-4637.
26. Fagot J-P, Boutrelle A, Ricordeau P, et al. HPV vaccination in France: Uptake, costs and issues for the national health insurance. Vaccine 2011;29:3610-3616.
27. Moulis G, Sailler L, Sommet A, et al. Prevalence of pneumococcal vaccination in adult immune thrombocytopenia patients exposed to rituximab or to splenectomy. Eur J Haematol 2013;90:438-439.
28. Vaccination schedule and recommendations from the "Haut conseil de la santé publique" in France 2009. Available at: http://www.invs.sante.fr/beh/2009/16_17/beh_16_17_2009.pdf. Accessed on July 1, 2014.
29. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-1139.
30. Coignard-Biehler H, Lanternier F, Hot A, et al. Adherence to preventive measures after splenectomy in the hospital setting and in the community. J Infect Public Health 2011;4:187-194.
31. Pickering J, Campbell H. An audit of the vaccination and antibiotic prophylaxis practices amongst patients splenectomised in lothian. Health Bull (Edinb) 2000;58:390
32. Brigden ML, Pattullo A, Brown G. Pneumococcal vaccine administration associated with splenectomy: the need for improved education, documentation, and the use of a practical checklist. Am J Hematol 2000;65:25-29.
33. Ejstrud P, Kristensen B, Hansen JB, et al. Risk and patterns of bacteraemia after splenectomy: A population-based study. Scand J Infect Dis 2000;32:521
34. Langley JM, Dodds L, Fell D, Langley GR. Pneumococcal and influenza immunization in asplenic persons: A retrospective population-based cohort study 1990-2002. BMC Infect Dis 2010;10:219
35. Perricone C, Ceccarelli F, Nesher G, et al. Immune thrombocytopenic purpura (ITP) associated with vaccinations: A review of reported cases. Immunol Res 2014;60:226-235.
36. Rinaldi M, Perricone C, Ortega-Hernandez O-D, et al. Immune thrombocytopaenic purpura: an autoimmune cross-link between infections and vaccines. Lupus 2014;23:554-567.
37. Moulis G, Sommet A, Sailler L, et al. French association of regional pharmacovigilance centers. Drug-induced immune thrombocytopenia: A descriptive survey in the french PharmacoVigilance database. Platelets 2012;23:490-494.
38. Assurance Maladie. Vaccinations 2014. Available at: http://www.ameli-sante.fr/vaccinations/reaction-organisme-face-aux-virus.html. Accessed on July 1, 2014.
39. Arrêté du 11 juillet 2012 relatif à la mise en ouvre du système national d'information interrégimes de l'assurance maladie. J Officiel de la République Française 2012;0171:texte 10. Available at: http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000026221180&dateTexte=&categorieLien=id. Accessed on August 27, 2013.
40. Arrêté du 19 juillet 2013 relatif à la mise en ouvre du système national d'information interrégimes de l'assurance maladie. J Officiel De La République Française 2013;0187:texte 3.
41. Blanchard-Rohner G, Pollard AJ. Sustaining immunity after immunization against encapsulated bacteria. Hum Vaccin 2008;4:309-312.
42. Vaccination schedule and recommendations from the "Haut conseil de la santé publique" in France 2014. Available at: http://www.sante.gouv.fr/IMG/pdf/Calendrier_vaccinal_ministere_sante_2014.pdf. Accessed on July 1, 2014.